Novartis reports positive Phase III results for remibrutinib in RMS

Phase 3positiveremibrutinibPositive

AI Analysis

Summary

Novartis announced positive Phase 3 results for remibrutinib, its oral BTK inhibitor, which met primary endpoints in two trials for adults with relapsing multiple sclerosis.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Met primary endpoint in two Phase III trials for adults with relapsing MS

Importance:8/10

Sentiment:

0.80

BTK inhibitororal medicationPhase 3multiple sclerosisrelapsing MS

Related Companies

$NVS

Read the original article

Published by Clinical Trials Arena on September 1, 2026 9:27 AM

Read Original